Tobramycin inhalation - Pulmoflow

Drug Profile

Tobramycin inhalation - Pulmoflow

Alternative Names: Kitabis Pak

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator PARI Pharma GmbH; PulmoFlow
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 21 Jul 2015 The US FDA lists KitabisTM Pak on the Prefered Drug List
  • 16 Mar 2015 The US FDA lists Kitabis™ Pak in the Orange Book as a therapeutic equivalent of TOBI® (tobramycin inhalation solution, USP)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top